Certara (NASDAQ:CERT) Shares Gap Down – What’s Next?

Certara, Inc. (NASDAQ:CERT) shares gapped down prior to trading on Thursday . The stock had previously closed at $6.03, but opened at $5.73. Certara shares last traded at $5.7540, with a volume of 535,302 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Barclays cut their target price on Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. KeyCorp lowered their price target on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. TD Cowen reissued a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Finally, BMO Capital Markets dropped their price target on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.85.

Certara Stock Performance

The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The stock has a market capitalization of $861.86 million, a P/E ratio of -55.40 and a beta of 1.49. The company has a fifty day moving average of $5.60 and a two-hundred day moving average of $7.07.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The firm had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same quarter in the previous year, the company earned $0.14 EPS. The company’s quarterly revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities analysts anticipate that Certara, Inc. will post 0.24 EPS for the current year.

Institutional Investors Weigh In On Certara

Institutional investors and hedge funds have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. boosted its holdings in Certara by 2,733.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after purchasing an additional 2,870 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Certara by 28.1% during the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after purchasing an additional 2,871 shares during the period. Finally, Chicago Partners Investment Group LLC bought a new position in shares of Certara in the 1st quarter worth about $78,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.